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Abstract: Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable
predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive
and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs):
We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform
with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression
from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched
CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection
of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited
to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor
cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such
as AR-V7 from non-invasive blood samples, so-called blood biopsies.
Keywords: biomarker; androgen receptor; AR-V7; prostate cancer; ddPCR; CTC
1. Introduction
The insight that cancers, even of the same type, show strong inter- and intra-patient heterogeneity
has emerged in recent years. Tumor biomarkers are most commonly conceptualized as specific
cellular, biochemical or molecular alterations that characterize heterogeneous subcategories of cancers.
Consequently, patient management increasingly relies on the detection of such tumor biomarkers to
predict prognosis, guide therapies and monitor treatment response as well as the development of
specific resistance mechanisms [1]. The number of identified actionable biomarkers (biomarkers that
determine the best type of therapy) and the generation of novel targeted drugs are currently increasing
faster than ever, leading to major changes in personalized therapy and clinical praxis.
Some serum proteins, such as the prostate specific antigen (PSA) in prostate cancer (PCa) and
carcinoembryonic antigen (CEA) in colorectal cancer, are well established biomarkers and clinically
widely used, although their correlation with other disease progression parameters is not always
ideal [2,3]. More recently, there has been a trend towards analyzing cancer associated gene expression,
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mutations, amplifications or gene expression variants, which can be very specific, and may predict
response and resistance to certain therapies. Some of these assays have already been validated and
adopted as part of clinical practice. For instance the detection of v-Raf murine sarcoma viral oncogene
homolog B (BRAF) V600E mutation is now decisive for melanoma treatment options that involve
targeted BRAF kinase inhibitors, and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)
mutations in colorectal cancer patients predict resistance to anti-epithelial growth factor receptor
(EGFR) monoclonal antibody based therapy (panitumumab and cetuximab) [4,5].
Traditionally, such molecular biomarkers are examined in excised tumor tissue or fine needle
biopsies at a single timepoint in the disease course. However, such biopsies are not always available
or informative [6]. To progress targeted therapies more broadly into the clinic, it is desirable to
detect biomarkers from non-invasive, easily accessible biopsies that are ideally of modest cost.
Additionally, repeated biopsies should be feasible to enable continuous monitoring of changes in
biomarkers during treatment and development of drug resistance. To that end, blood biopsies are
becoming increasingly attractive because various tumor-derived biomarkers can be screened from
blood. Tumors release entire circulating tumor cells (CTCs) and circulating tumor nucleic acids (ctDNA
and ctRNA) into the blood stream, and screening these for tumor associated genetic changes is
becoming increasingly feasible [6,7]. While these kinds of assays still need further validation before
they can be adopted into clinical practice, blood-based assays are extremely appealing to clinicians and
researchers. Importantly these assays are known to detect evidence of the common tumor heterogeneity,
which needs to be accounted for in biomarker analysis [8].
In PCa, genetic changes in the androgen receptor (AR), such as point mutation and gene
amplification, render the receptor independent of upstream testosterone levels and cause resistance
against androgen deprivation therapy (ADT), which is the predominant first line therapy for advanced
disease [9]. Thus far, AR amplification screening using fluorescent in situ hybridization (FISH)
and point mutation screening with PCR-based methods from CTC enriched samples have been
reported [10–13]. AR transcriptional variants, for example, AR-V7 and AR-V567es, which encode
constitutively active, truncated receptor proteins, cause ligand independent AR activation and are
clinically relevant [14]. ADT-drug exposure rapidly induces AR-V7 expression in in vivo models
and patient PCa cells, likely to compensate loss of regular AR signaling [9,15]. More importantly,
the detection of AR-V7 in PCa CTCs has been correlated with metastatic castrate resistant prostate
cancer (CRPC) and resistance against enzalutamide and abiraterone, and potentially superior clinical
outcomes for patients on taxane therapy, though response to cabazitaxel has been shown to be
independent of AR-V7 status [16–18]. Taken together, this suggests that AR-V7 may be a useful
biomarker on which to base therapy initiation or therapy changes.
Here, we present development of a reliable droplet digital PCR based method to detect AR-V7
and total AR expression in PCa patient CTCs enriched by the IsoFlux system. Our assay has high
specificity and sensitivity and detects AR-V7 expression in as little as five AR-V7 PCa cells spiked to
produce a modeled CTC sample, and was confirmed in PCa patient CTCs.
2. Results and Discussion
2.1. Assay Optimization
Droplet digital PCR (ddPCR), utilizing Taqman PCR principles, is a novel and sensitive method to
detect rare mutations, gene expression and copy number variations in samples with limited amounts
of nucleic acid templates [19]. To optimize the detection of total AR and AR-V7 transcript expression
with ddPCR from total RNA we initially determined the appropriate annealing temperature for our
assay using prostate cancer cell line total RNA as basis for ddPCR cDNA template synthesis. At 55 ˝C,
annealing temperature for ddPCR reactions total AR and AR-V7 amplicon containing events (droplets)
showed the best separation from empty baseline events and good PCR amplification was achieved
(Figure 1).
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Figure 1. Annealing temperature optimization. Temperature gradient droplet digital PCR (ddPCR) 
was used to decide on the optimal annealing temperature for the assay. cDNA derived from 200 pg 
of cell line RNA was used per ddPCR reaction, multiplexed in the presence of probes and primers  
for both products. AR-V7 ddPCR products are shown in blue and total AR products in green.  
(A) Fluorescence product separation from background fluorescence from VCaP cell line AR-V7  
FAM and total AR HEX reactions with indicated annealing temperatures is compared in 1-D graph 
presentation; (B) 2D separation of PCR products from VCaP; and (C) 22Rv1 prostate cancer (PCa) cell 
lines are depicted for optimized annealing temperature of 55 °C. 
2.2. Assay Specificity 
To test assay specificity we determined total AR and AR-V7 expression in a cohort of PCa cell 
lines: 22Rv1, VCaP, C4-2, LNCaP, C4-2B, LAPC4, and PC3 and the b-lymphocyte line WME-099 
(Table 1). Amongst the PCa cell lines, 22Rv1 showed high AR-V7 levels and AR-V7 versus total AR 
expression ratios (26%). This agrees with previous studies, using immunoblots to discriminate 
between full length AR and AR-V7 [20,21]. VCaP, known to carry AR gene amplification [22], 
expectedly expressed the highest level of total AR transcript, which was two to seven fold the level 
of other AR positive cell lines. LNCaP and its derivates, C4-2 and C4-2B, had consistently less than 
one AR-V7 copy per cell, and interestingly C4-2 expressed reduced levels of total AR transcript 
compared to the related C4-2B and parental LNCaP cells. LAPC4 had low levels of total AR 
expression, as previously reported [23], and no detectable AR-V7. PC3 cells are known to be  
AR-negative [24] and expectedly expressed neither total AR nor AR-V7 as did the control WME-099 
lymphocytes. Similarly, we assayed healthy donor peripheral blood mononuclear cells (PBMCs)  
(5 male, 1 female sample), which had negligible total AR and no AR-V7 expression, confirming data 
from normal blood cells in previous reports (Table 2) [13,25]. 
Table 1. Expression levels and ratio of AR-V7 and total AR in cell lines. 
 22Rv1 VCaP C4-2 LNCaP C4-2B LAPC4 PC3 WME099
AR-V7 
(copies/cell) 4.6 1.2 0.5 0.4 0.4 0.0 0.0 0.0 
AR-V7  
95% CI 2.6–6.6 0.8–1.8 0.2–0.9 0.1–0.8 0.1–0.7 0.0–0.2 0.0–0.3 0.0–0.2 
Total-AR 
(copies/cell) 17.6 97.0 24.7 44.4 47.8 13.4 0.0 0.1 
Total-AR  
95% CI 14.4–21.0 82.7–111.4 22.3–27.0 38.9–49.9 44.4–51.1 11.5–15.2 0.0–0.3 0.0–0.4 
V7/AR (%) 26.0 1.3 1.9 0.9 0.7 0.0 0.0 0.0 
Copies/cell were calculated from copies/µL droplet digital PCR (ddPCR) reaction data by  
accounting for the cDNA input corresponding to 500 pg RNA, and assuming 30 pg RNA/cell;  
CI: confidence interval. 
Figure 1. Annealing temperature optimization. Temperature gradient droplet digital PCR (ddPCR)
was used to decide on the optimal annealing temperature for the assay. cDNA derived from 200 pg of
cell line RNA was used per ddPCR reaction, multiplexed in the presence of probes and primers
for both products. AR-V7 ddPCR products are shown in blue and total AR products in green.
(A) Fluorescence product separation from background fluorescence from VCaP cell line AR-V7 FAM and
total AR HEX reactions with indicated annealing temperatures is compared in 1-D graph presentation;
(B) 2D separation of PCR products from VCaP; and (C) 22Rv1 prostate cancer (PCa) cell lines are
depicted for optimized annealing temperature of 55 ˝C.
2.2. Assay Specificity
To test assay specificity we determined total AR and AR-V7 expression in a cohort of PCa cell lines:
22Rv1, VCaP, C4-2, LNCaP, C4-2B, LAPC4, and PC3 and the b-lymphocyte line WME-099 (Table 1).
Amongst the PCa cell lines, 22Rv1 showed high AR-V7 levels and AR-V7 versus total AR expression
ratios (26%). This agrees with previous studies, using immunoblots to discriminate between full length
AR and AR-V7 [20,21]. VCaP, known to carry AR gene amplification [22], expectedly expressed the
highest level of total AR transcript, which was two to seven fold the level of other AR positive cell lines.
LNCaP and its derivates, C4-2 and C4-2B, had consistently less than one AR-V7 copy per cell, and
interestingly C4-2 expressed reduced levels of total AR transcript compared to the related C4-2B and
parental LNCaP cells. LAPC4 had low levels of total AR expression, as previously reported [23], and
no detectable AR-V7. PC3 cells are known to be AR-negative [24] and expectedly expressed neither
total AR nor AR-V7 as did the control WME-099 lymphocytes. Similarly, we assayed healthy donor
peripheral blood mononuclear cells (PBMCs) (5 male, 1 female sample), which had negligible total AR
and no AR-V7 expression, confirming data from normal blood cells in previous reports (Table 2) [13,25].
Table 1. Expression levels and ratio of AR-V7 and total AR in cell lines.
22Rv1 VCaP C4-2 LNCaP C4-2B LAPC4 PC3 WME099
AR-V7
(copies/cell) 4.6 1.2 0.5 0.4 0.4 0.0 0.0 0.0
AR-V7
95% CI 2.6–6.6 0.8–1.8 0.2–0.9 0.1–0.8 0.1–0.7 0.0–0.2 0.0–0.3 0.0–0.2
Total-AR
(copies/cell) 17.6 97.0 24.7 44.4 47.8 13.4 0.0 0.1
Total-AR
95% CI 14.4–21.0 82.7–111.4 22.3–27.0 38.9–49.9 44.4–51.1 11.5–15.2 0.0–0.3 0.0–0.4
V7/AR (%) 26.0 1.3 1.9 0.9 0.7 0.0 0.0 0.0
Copies/cell ere calculated from copies/µL droplet digital PCR (ddPCR) reaction data by accounting for the
cDNA input corresponding to 500 pg RNA, and assuming 30 pg RNA/cell; CI: confidence interval.
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Table 2. Negligible expression levels of AR-V7 and total AR in blood cells.
PBMC-1 PBMC-2 PBMC-3 PBMC-4 PBMC-5 PBMC-6
AR-V7 (copies/cell) 0 0 0 0 0 0
AR-V7 95% CI 0–0.004 0–0.003 0–0.003 0–0.003 0–0.003 0–0.002
Total-AR (copies/cell) 0 0 0.002 0 0.001 0
Total-AR 95% CI 0–0.004 0–0.003 0–0.00 0–0.003 0–0.006 0–0.003
Four thousand peripheral blood mononuclear cells (PBMCs) per healthy donor were processed the same way
as patient circulating tumor cell (CTC) samples to determine background AR-V7 and total AR expression.
Copies/cell was calculated from copies/µL ddPCR reaction data by accounting for the cDNA input;
CI: confidence interval.
2.3. Assay Sensitivity
One mammalian cell contains approximately 10–30 pg of total RNA dependent on cell type
and physiological state [26]. To test the sensitivity of our new ddPCR assay we titrated down the
amount of purified total input RNA from AR-V7 positive 22Rv1 cells to approximately the amount
expected from a single cell (2000 down to 15.5 pg) either alone, or by dilution in a constant amount
of AR-V7-negative total RNA from WME-099 cells as would be expected in an RNA extract from a
CTC sample with residual lymphocytes. As presented in Figure 2, the sensitivity of total AR and
AR-V7 detection is able to capture the input RNA expected from a single cell regardless of lymphocyte
RNA background. This was also validated in a similar dilution series with RNA template from VCaP
cells despite the lower expression of AR-V7 in these cells (data not shown). To more thoroughly
define what number of PCa CTCs is required in a typical IsoFlux-processed sample to reliably detect
AR-V7 and total AR expression with our AR-V7 assay, we spiked defined numbers of 22Rv1 cells
into 4000 PBMCs. This lymphocyte number is based on the average total cell count post IsoFlux
CTC enrichment (see Table 3). The resulting samples were processed for ddPCR AR-V7 screening in
the same way as IsoFlux enriched patient CTC samples, with Figure 3 demonstrating that our assay
reliably detects relevant AR-V7 expression from one spiked cell into 4000 lymphocytes. However this
is only true in two out of three replicates. Whether this reflects true technical assay limitations,
such as ability to consistently reverse transcribe RNA and synthesize cDNA, or whether in fact not
all 22Rv1 cells express AR/AR-V7, remains speculation at present. The latter is supported by our
data which show that statistically some cell lines express less than one copy AR-V7 per cell (Table 1),
as well as previous AR-V7 detection in only 74% of individual 22Rv1 cells analyzed by quantitative
PCR (qPCR) [27]. Thus expression of AR and its variants may be regulated by physiological events,
such as cell cycle dependent regulation; indeed AR has been proposed to be transcriptionally repressed
by the retinoblastoma protein [28]. This may also help in explaining that although AR reportedly
can be lost in vivo in advanced prostate cancer tissue, AR-loss was to our knowledge only found in
a heterogeneous manner [29]. Consequently, a conservative interpretation of the assay in our hands
is that we can confidently detect AR-V7 status in the presence of at least five prostate cancer CTCs.
This allows, even in the presence of tumor cell heterogeneity, reproducible detection of enough ddPCR
events positive for total AR, or importantly, AR-V7. Thus, our AR-V7 detection assay with ddPCR has
high specificity and sensitivity, sufficient to reliably define AR-V7 expression for most of our advanced
PCa patient samples, which have a median CTC number of 32 (range: 3–184, Table 3). By contrast,
detection efficiency for other methods has not been documented in detail in most other studies but we
note that AR-V7 was detected in samples with a range of one to a minimum of ten CTCs [18,27].
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dotted lines, duplicates by yellow dotted lines; RNA concentration inputs within the range predicted 
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1 0 96 0 31 2700
2 0 0 n/a 7 2897
3 * 0 0 n/a 3 6919
4 0 n/a 7 6800
5 0 0 9 3848
6 0 0 n/a 56 3400
7 0 80 0 8 3380
8 0 0 n/a 7 2732
9 0 8 0 6 5464
10 0 24 0 65 7366
CRPC
11 0 296 0 25 3182
12 0 360 0 28 6229
13 0 0 n/a 102 3997
14 0 88 0 35 1566
15 0 16 0 184 3224
16a 0 24 0 82 3715
16b 0 960 0 81 2058
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Table 3. Cont.








17a 0 0 n/a 122 1163
17b 32 1152 2.5 12 3686
18 8 1000 0.8 47 1505
19 16 768 2.3 70 1820
20 104 5336 1.9 10 8900
21 264 37,008 0.7 39 1418
22 360 20,880 1.7 44 4600
23 880 153,120 0.6 12 2077
24 1632 74,824 2.2 56 4434
AR-V7 and total AR are normalized from template input to represent copy number per 8 mL blood sample.
Patient 16 and 17 had consecutive samples evaluated (b) was analyzed ~3 months following sample (a).
n/a: not applicable; * note, patient 3 has only 3 detected CTCs and is, thus, below our conservatively estimated
AR-V7 detection limit.
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The ddPCR assay was validated by testing twenty six CTC samples from twenty-four PCa 
patients after IsoFlux CTC isolation for expression of AR-V7. AR-V7 was detected in 30.8% of CTC 
samples (8/26): no AR-V7 was detected in any (0/10) of the HSPC (hormone sensitive prostate cancer) 
samples (note, HSPC patient 3 was with only three CTCs below our conservatively estimated AR-V7 
detection limit) whereas AR-V7 was detected in 50% (8/16) of CRPC samples. Detection of AR-V7 in 
Figure 3. Modeled CTC samples. Prostate cancer CTC samples were modeled by spiking indicated
numbers of 22Rv1 cells into 4000 lymphocytes from healthy donors by micro-manipulation using
the CellCelector (ALS, Jena, Germany). Data was derived from three independent experiments.
(A) Representative 2D ddPCR plots from spike-in experiment (0, 1, 5, 10 22Rv1 cells, black circles
highlight AR-V7 and total AR events); (B) copy numbers of total AR and AR-V7 dependent on 22Rv1
cell number.
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2.4. AR-V7 Expression in Patient Circulating Tumor Cell (CTC) Samples
The ddPCR assay was validated by testing twenty six CTC samples from twenty-four PCa patients
after IsoFlux CTC isolation for expression of AR-V7. AR-V7 was detected in 30.8% of CTC samples
(8/26): no AR-V7 was detected in any (0/10) of the HSPC (hormone sensitive prostate cancer) samples
(note, HSPC patient 3 was with only three CTCs below our conservatively estimated AR-V7 detection
limit) whereas AR-V7 was detected in 50% (8/16) of CRPC samples. Detection of AR-V7 in CTC
positive patient samples is within the range reported by others for qPCR AR-V7 assays (29%–55%)
and above that found by immunocytostaining (18%) [13,16–18,27]. As expected, residual lymphocyte
counts had no effect on detectability of either form of the AR in our assay. AR-V7 expression in
positive patient samples ranged from 8 to 1632 copies per eight mL blood. Patient 18 with eight
AR-V7 copies had a CTC count of 47, highlighting tumor cell heterogeneity since clearly not all
cells contribute to AR-V7 expression, a finding also observed for patient 19 who had sixteen AR-V7
copies detected from 70 CTCs. The lowest CTC count in a patient sample with detectable AR-V7
was ten (patient 20). Since we detected as many as 104 copies of AR-V7 from only 10 CTCs in this
sample, it is likely our assay will detect AR-V7 in samples with considerably lower CTC counts as
long as these cells express AR-V7. We will need to analyze larger patient cohorts to confirm this
finding, but for now a minimum of five CTCs remains our conservatively estimated detection limit
to confidently call a sample AR-V7-negative, based on our 22Rv1 spiking data and expected CTC
heterogeneity. Interestingly, for two patients we tested samples taken approximately 3 month apart
(patient 16 and 17). Both patients were considered to have CRPC at both time points, but patient 17
changed from AR-V7 negative to positive. He had a PSA of 76.6 at the first CTC sampling but showed
disease progression radiologically, as well as resistance to Abiraterone with an increase of his PSA
to 193.7 by the time his second sample was taken. Patient data are presented in Table 3. Despite the
small patient cohort studied here for method validation, Table 4 summarizes that AR-V7 detection
significantly correlated with CRPC (p = 0.008).
Table 4. AR-V7 status of circulating tumor cells (CTCs) correlates to hormone resistance.
AR-V7 HSPC CRPC Total
+ve 0 8 8
´ve 10 8 18
total 10 16 26
Association of AR-V7 with CRPC is statistically significant p = 0.008. Two of fourteen CRPC patients were
analyzed at two time points (three month intervals) with one of them changing from AR-V7 negative to positive
for the second time point. (total = total sample number; +ve: positive; ´ve: negative).
3. Materials and Methods
3.1. Cell Lines
The human PCa cell lines LNCaP, VCaP, C4-2, C4-2B, PC3, LAPC, 22Rv1, as well as the human
b-lymphocyte cell line WME-099, were either recently purchased (ATCC, in vitro Technologies,
Lane Cove, Australia) or authenticated (AGRF, Melbourne, Australia). Cells were maintained in
RPMI media (Lonza, Basel, Switzerland) supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA)
in a humidified incubator with 5% CO2 at 37 ˝C.
3.2. Patients
Twenty-four patients diagnosed with high risk PCa and positive for CTCs were recruited at
Liverpool Hospital. Of the twenty-four patients, twenty-two had metastatic disease, with the remaining
two having biochemical recurrent disease (Gleason grade 7 or greater). All patients and healthy blood
donors gave informed consent to participate in the study. The study was conducted in accordance with
the Declaration of Helsinki, and the protocol was approved by the South Western Sydney Local Health
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District Ethics Committee (Ref: HREC/13/LPOOL/158, 2nd September 2013). Whole blood from
patients or healthy donors was drawn in 9 mL K3E K3EDTA-tubes (Greiner Bio-one, Kremsmünster,
Austria) after discarding the first 2 mL blood to avoid contamination with epithelial skin cells.
Patients were considered to have CRPC if they had experienced new metastases, progression of
metastases or a rise in PSA despite adequate castration serum testosterone levels <1.7 nmol/L [30].
3.3. CTC Enrichment
CTC enrichment was performed with the IsoFlux CTC enrichment kit (Fluxion, San Francisco,
CA, USA) according to manufacturer’s instructions. Briefly, PBMCs were separated from 8 mL of
blood using 50 mL SepMate tubes and Lymphoprep (STEMCELL, Melbourne, Australia) according to
the manufacturer’s instructions. PBMCs were once washed with PBS and transferred into a 1.5 mL
Low-Protein-Bind tubes (Eppendorf, Hamburg, Germany) with 40 µL anti-human EpCAM conjugated
immunomagnetic beads and 40 µL Fc blocker and incubated at 4 ˝C with slow agitation for 1.5 h.
Cells were then loaded into isolation cartridges and CTCs were isolated using the IsoFlux CTC
enrichment system and run using the standard separation protocol (Fluxion). Isolated CTCs were
either enumerated or frozen at ´80 ˝C for later down-stream analysis.
3.4. Immunocytostaining and CTC Enumeration
CTCs were immunocytostained for the presence of cytokeratin, CD45 and nuclei by Hoechst
dye using the IsoFlux CTC enumeration kit (Fluxion) according to the manufacturer’s instructions.
CTCs mounted in 24-well glass bottom plates were visualized and scanned with Olympus Ix71
(Olympus, Tokyo, Japan) mounted with an automated stage ProScan III (PRIOR) (10ˆ objective).
The exposure time for Hoechst, CD45 and cytokeratin are 2, 200 and 400 ms, respectively. CD45 negative
cells with positive Hoechst and cytokeratin staining were considered to be CTCs and counted manually
from scanned images. Total cell numbers (i.e., including residual blood cells) were also determined in
the Hoechst channel using the Olympus CellSens Software “count and measure” plugin (Tokyo, Japan).
3.5. RNA Extraction and cDNA Synthesis
Total RNA from cell lines was extracted with the ISOLATE II RNA Mini Kit (Bioline, Sydney,
Australia) and any residual genomic DNA contamination was removed by on-column DNAse I
treatment for 15 min. RNA was eluted in 50 µL RNase-free H2O. RNA quality and quantity were
measured using the NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA). cDNA synthesis was
performed from 1 µg total RNA with the SensiFAST cDNA Synthesis kit (Bioline, Sydney, Australia).
Total RNA from IsoFlux CTC samples or healthy control PBMCs was extracted with the RNA
purification Micro kit (Norgen Biotek Corp., Thorold, ON, Canada) and double-eluted in a total volume
of 30 µL RNase-free H2O. 15 µL of this RNA was converted into cDNA with the SensiFAST cDNA
Synthesis kit (Bioline). Healthy donor PBMCs consisted of 4000 cells to mimic IsoFlux CTC samples.
3.6. Droplet Digital PCR (ddPCR)
Primers and Taqman probes were designed using NCI primer software (Table 5). ddPCR samples
for total AR and AR-V7 were set up with 20 µL reaction mixture containing 10 µL ddPCR Supermix
for Probes, no dUTP (Bio-Rad, Hercules, CA, USA), 500 nM of each forward primer (FP) and reverse
primer (RP) and 250 nM probe (FAM and HEX). Droplets were generated with 70 µL oil using a QX200
droplet generator (Bio-Rad). Amplification was performed at 95 ˝C, 10 min; followed by 40 cycles
of 94 ˝C, 30 s and 55 ˝C (or 60 ˝C for actin) 1 min using a C1000 Touch thermocycler (Bio-Rad).
After amplification, the droplets were read on a QX200 droplet reader (Bio-Rad) and analyzed with
QuantaSoft software V1.7.4 (Bio-Rad). The total error calculated by the software was used as the 95%
confidence intervals.
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3.7. Modeling CTC Samples and Single Cell Micromanipulation
Single cells were isolated using the CellCelector (ALS GmbH, Jena, Germany) as described
before [31]. In brief, 30 µm capillaries were used to pick live 22Rv1 cells under Brightfield at
20ˆ magnification from 2% BSA-coated glass slides. Selected cells were aspirated with a volume
of 20–100 nL and deposited into PCR tubes containing 100 µL RL buffer (ISOLATE II RNA Mini Kit,
Bioline) and combined with 250 µL RL buffer containing 4000 healthy donor PBMCs. Samples were
processed for RNA extraction and cDNA synthesis, as outlined for IsoFlux CTC samples.
3.8. Statistics
To establish the relationship between hormone sensitivity and AR-V7 detection, we performed
a Fisher’s Exact Test using SPSS Statistics (IBM) software package version 23 (New York, NY, USA).
4. Conclusions
We developed a specific and sensitive ddPCR-based assay to determine AR-V7 expression in
PCa CTC samples that can reliably detect AR-V7 expression from CTC positive patient samples.
The advantage of the ddPCR based assay is that it determines not only AR-V7 positivity but actual
transcript copy numbers and that allows in some instances to detect heterogeneity of AR-V7 gene
expression without further separation of individual CTCs from residual lymphocytes and other CTCs
after immunomagnetic CTC isolation using the IsoFlux platform. Although we were able to detect
AR-V7 from a single cell, we conservatively estimate that AR-V7 can be reliably determined in samples
with at least five CTCs, as this takes into account heterogeneity of AR-V7 expression as evident in
two of our patient samples (patient 18 and 19). In our small proof of concept patient set, association
of AR-V7 detection was significantly associated with development of CRPC and we are currently
screening larger patient cohorts to confirm the robustness of our approach and association with clinical
parameters. Our assay is likely adaptable for CTCs isolated by other methods or for circulating tumor
RNA, which can be isolated from processed plasma samples.
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CRPC castrate resistant prostate cancer
HSPC hormone sensitive prostate cancer
CTC circulating tumor cell
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ctNA circulating tumor nucleic acid
PSA prostate specific antigen
CEA carcinoembryonic antigen
EGFR epidermal growth factor receptor
ADT androgen deprived therapy
EpCam epithelial cell adhesion molecule
CK cytokeratin
PBMC peripheral blood mononuclear cell
ddPCR droplet digital PCR
FP forward primer
RP reverse primer
FISH fluorescent in situ hybridysation
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